Ajay Dubey, MD
Radiation Oncology · Bedford, TXNPI 1548207509
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $183 of the $207 with a category attached, or 88.5%. It is spread thinly across 8 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $77, 3.1 times the $25 reported in 2019. That places this record below the midpoint for radiation oncology clinicians in TX, where the typical reported total is $554.
Across 8 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Napo Pharmaceuticals Inc$35
- Pharmaessentia USA Corporation$30
- Medtronic$29
- Bayer$25
- Myovant Sciences Inc.$24
- Daiichi Sankyo Inc.$24
- plus $40 from 2 others
What the payments were for
- Food & beverage$18388%
- Education$2412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Napo Pharmaceuticals Inc | 1 | $35 |
| Pharmaessentia USA Corporation | 1 | $30 |
| Medtronic | 1 | $29 |
| Bayer | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Novartis | 1 | $18 |
How this compares
$207 in reported general payments places this provider in the 30th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 14 | $585 |
| Ondansetron Hcl | 20 | $429 |
| Dexamethasone | 43 | $363 |
| Tamsulosin Hcl | 51 | $341 |
| SsdSilver Sulfadiazine | 22 | $336 |
| Ondansetron OdtOndansetron | 12 | $278 |
| Triamcinolone Acetonide | 22 | $161 |
| Pantoprazole Sodium | 13 | $101 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Bedford
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
- Abhilasha PatelHouston$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.